.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,064,148

« Back to Dashboard

Claims for Patent: 7,064,148

Title:Chloride channel opener
Abstract:Disclosed is a novel use of a prostaglandin compound as a chloride channel opener. According to the instant invention, chloride channels in a mammalian subject can be opened by a prostaglandin compound to facilitate chloride ion transportation.
Inventor(s): Ueno; Ryuji (Montgomery, MD), Cuppoletti; John (Cincinnati, OH)
Assignee: Sucampo AG (Zug, CH)
Application Number:10/231,341
Patent Claims: 1. A method for treating disease by opening ClC channels in a mammalian subject, wherein the disease is selected from the group consisting of myotonia atrophica, calculus renum, constipation, anxiety, insomnia, epilepsia, anesthesia, asthma, bronchitis and neuropathy, which comprises administering an effective amount of a prostaglandin compound to the subject, wherein said prostaglandin compound is the compound as shown by the following general formula (I): ##STR00013## wherein L, M and N are hydrogen atom, hydroxy, halogen atom, lower alkyl, hydroxy(lower)alkyl, or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring of formula (I) may have one or more double bonds; A is --CH.sub.2OH, --COCH.sub.2OH, --COOH or a pharmaceutically acceptable salt, ether, ester or amide thereof; B is --CH.sub.2--CH.sub.2--, --CH.dbd.CH-- or --C.ident.C--; Zis ##STR00014## wherein R.sub.4 and R.sub.5 are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy(lower)alkyl, wherein R.sub.4 and R.sub.5 are not hydroxy and lower alkoxy at the same time; R.sub.1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo, or aryl, and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, or aryloxy; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; or aryloxy.

2. The method as described in claim 1, wherein said prostaglandin compound is 13,14-dihydro-16-mono or dihalogen-prostaglandin compound.

3. The method as described in claim 1, wherein said prostaglandin compound is 13,14-dihydro-15-keto-16-mono or dihalogen-prostaglandin compound.

4. The method as described in claim 1, wherein said prostaglandin compound is 13,14-dihydro-16-mono or difluoro-prostaglandin compound.

5. The method as described in claim 1, wherein said prostaglandin compound is 13,14-dihydro-15-keto-16-mono or difluoro-prostaglandin compound.

6. The method as described in claim 1, wherein said prostaglandin compound is 13,14-dihydro-16-mono or dihalogen-prostaglandin E compound.

7. The method as described in claim 1, wherein said prostaglandin compound is 13,14-dihydro-15-keto-16-mono or dihalogen-prostaglandin E compound.

8. The method as described in claim 1, wherein said prostaglandin compound is 13,14-dihydro-16,16-difluoro prostaglandin E.sub.1 compound.

9. The method as described in claim 1, wherein said prostaglandin compound is 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1 compound or 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 compound.

10. The method as described in claim 1, wherein A is represented by the formula (V): --CONR'R'' (V) wherein R' and R'' are hydrogen, lower alkyl, aryl, alkyl- or aryl-sulfonyl, lower alkenyl or lower alkynyl.

11. The method as described in claim 10, wherein the prostaglandin compound is 13,14-dihydro-15-keto-16,16-difluoro-PGE.sub.1 N-ethyl amide.

12. The method as described in claim 10, wherein the prostaglandin compound is 13,14-dihydro-15-keto-16,16-difluoro-PGF.sub.1.alpha. N-ethyl amide.

13. A method for treating cystic fibrosis, which comprises by administrating an effective amount of a prostaglandin compound to a subject in need of such treatment, wherein said prostaglandin compound is a compound as shown by the following general formula (I): ##STR00015## wherein L, M and N are hydrogen atom, hydroxy, halogen atom, lower alkyl, hydroxy(lower)alkyl, or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring of formula (I) may have one or more double bonds; A is --CH.sub.2OH, --COCH.sub.2OH, --COOH or a pharmaceutically acceptable salt, ether, ester or amide thereof; B is --CH.sub.2--CH.sub.2--, --CH.dbd.CH-- or --C.ident.C--; Z is ##STR00016## wherein R.sub.4 and R.sub.5 are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy(lower)alkyl, wherein R.sub.4 and R.sub.5 are not hydroxy and lower alkoxy at the same time; R.sub.1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo, or aryl, and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is substituted with halogen, oxo, hydroxy, lower alkoxy, or lower aryloxy; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; or aryloxy, provided that Ra is substituted by halogen.

14. The method as described in claim 13, wherein said prostaglandin compound is 13,14-dihydro-16-mono or dihalogen-prostaglandin compound.

15. The method as described in claim 13, wherein said prostaglandin compound is 13,14-dihydro-15-keto-16-mono or dihalogen-prostaglandin compound.

16. The method as described in claim 13, wherein said prostaglandin compound is 13,14-dihydro-16-mono or difluoro-prostaglandin compound.

17. The method as described in claim 13, wherein said prostaglandin compound is 13,14-dihydro-15-keto-16-mono or difluoro-prostaglandin compound.

18. The method as described in claim 13, wherein said prostaglandin compound is 13,14-dihydro-16-mono or dihalogen-prostaglandin E compound.

19. The method as described in claim 13, wherein said prostaglandin compound is 13,14-dihydro-15-keto-16-mono or dihalogen-prostaglandin E compound.

20. The method as described in claim 13, wherein said prostaglandin compound is 13,14-dihydro-16,16-difluoroprostaglandin E.sub.1 compound.

21. The method as described in claim 13, wherein said prostaglandin compound is 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1 compound or 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 compound.

22. The method as described in claim 13, wherein A is represented by the formula (V): --CONR'R'' (V) wherein R' and R'' are hydrogen, lower alkyl, aryl, alkyl- or aryl-sulfonyl, lower alkenyl or lower alkynyl.

23. The method as described in claim 22, wherein the prostaglandin compound is 13,14-dihydro-15-keto-16,16-difluoro-PGE.sub.1 N-ethyl amide.

24. The method as described in claim 22, wherein the prostaglandin compound is 13,14-dihydro-15-keto-16,16-difluoro-PGF.sub.1.alpha. N-ethyl amide.

25. A method for treating a condition associated with reduced chloride ion permeability wherein the condition is selected from the group consisting of myotonia atrophica, calculus renum, anxiety, insomnia, epilepsia, anesthesia and neuropathy, which comprises administering to a subject in need thereof an effective amount of a prostaglandin compound as shown by the following general formula (I): ##STR00017## wherein L, M and N are hydrogen atom, hydroxy, halogen atom, lower alkyl, hydroxy(lower)alkyl, or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring of formula (I) may have one or more double bonds; A is --CH.sub.2OH, --COCH.sub.2OH, --COGH or a pharmaceutically acceptable salt, ether, ester or amide thereof; B is --CH.sub.2--CH.sub.2--, --CH.dbd.CH-- or --C.ident.C--; Z is ##STR00018## wherein R.sub.4 and R.sub.5 are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy(lower)alkyl, wherein R.sub.4 and R.sub.5 are not hydroxy and lower alkoxy at the same time; R.sub.1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo or aryl, and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, or aryloxy; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; or aryloxy.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc